MaaT Pharma

• MaaT Pharma has successfully entered into a €37.5 million venture debt facility with the European Investment Bank
• The total amount of €37.5 million consists of four committed tranches with a tenor of 6-8 years dependent on the tranche
• The facility will enable MaaT Pharma to advance its late-stage hemato-oncology clinical programs including its lead-asset Xervyteg® for the treatment of acute Graft-versus Host Disease which has been submitted with the EMA for regulatory approval
• Eric Soyer, Chief Financial Officer at MaaT Pharma: “We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT Pharma’s growth on bringing the potential first microbiome-based therapy to market in Europe
• Van Lanschot Kempen acted as Financial Adviser, assisting MaaT Pharma throughout the process with overall process management and supporting MaaT Pharma in the negotiations of the transaction. “Van Lanschot Kempen has advised numerous European biotech companies in raising funding from the EIB. Their experience and expertise were instrumental during the successful negotiation, documentation, and timely closing of this meaningful transaction,” according to Eric Soyer, Chief Financial Officer at MaaT Pharma
• Following our previous involvement in MaaT Pharma’s successful IPO in November 2021 and capital increase in March 2025, we are proud to have assisted this repeat client in another financing transaction
• This transaction exemplifies Van Lanschot Kempen’s expertise in providing a wide range of financing solutions, including equity, structured finance, debt advisory and royalty financing. With >€1 billion in alternative financing transactions executed since 2020, underscoring strong expertise and market position in securing competitive, flexible and innovative financing solutions for European life sciences & healthcare companies at various stages

In the last eighteen months Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Co-Manager in the USD 748 million capital increase by Abivax
• Joint Bookrunner in the USD 201 million capital increase by Pharvaris
• Lead Manager in the USD 345 million capital increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €85 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank
• Lead Manager in the USD 1 billion capital increase by Zealand Pharma
• Lead Manager in the USD 460 million capital increase by Merus